Publications by authors named "Nahas Federico"
Purpose: To describe results of the Amyloid, Tau, Neurodegeneration (ATN) research framework classification in the Argentine-Alzheimer's Disease Neuroimaging Initiative (arg-ADNI) cohort.
Methods: Twenty-three patients with mild cognitive impairment (MCI), 12 dementia of Alzheimer's type (DAT), and 14 normal controls were studied following the ADNI2 protocol. Patients were categorized according to presence or absence of the biomarkers for amyloid beta (Aβ; A: amyloid positron emission tomography [PET] scan or cerebrospinal fluid [CSF] Aβ42), tau (T: CSF phosphorylated-tau), and neurodegeneration (N: CSF total-tau, fluorodeoxyglucose [FDG]-PET scan, or structural magnetic resonance imaging [MRI] scan).
A biological classification for Alzheimer's disease - Amyloid, Tau and Neurodegeneration (A/T/N): results from the Argentine-Alzheimer's Disease Neuroimaging Initiative.
Int Psychogeriatr
December 2019
The Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI) study is a longitudinal prospective cohort of 50 participants at a single institution in Buenos Aires, Argentina. Longitudinal assessments on a neuropsychological test battery were performed on 15 controls, 24 mild cognitive impairment (MCI) patients and 12 Alzheimer's disease (AD) dementia patients. In our study population, there was a high prevalence of positive AD biomarkers in the AD group, 92.
View Article and Find Full Text PDFPurpose: Argentina-Alzheimer's Disease Neuroimaging Initiative (Arg-ADNI) is the first ADNI study to be performed in Latin America at a medical center with the appropriate infrastructure. Our objective was to describe baseline characteristics and to examine whether biomarkers related to Alzheimer's disease (AD) physiopathology were associated with worse memory performance.
Patients And Methods: Fifteen controls and 28 mild cognitive impairment and 13 AD dementia subjects were included.
Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic.
Am J Alzheimers Dis Other Demen
September 2015
Article Synopsis
- Positron Emission Tomography (PET) can visualize fibrillar β-amyloid, which is important for assessing Alzheimer's Disease (AD), but merely detecting amyloid plaques isn't enough for a definitive diagnosis.
- The study grouped 144 patients into high and low pre-test probability categories based on clinical diagnoses related to AD, examining the prevalence of amyloid findings in different dementia syndromes.
- Results indicated that only normal controls and Dementia of Alzheimer's Type showed consistent diagnostic results, while other conditions like MCI and Frontotemporal Dementia displayed significant discrepancies between clinical evaluations and molecular imaging outcomes.